Diabetic nephropathy: The role of blood pressure and extracellular volume in its pathogenesis and treatment;Diabetische nefropathie: De rol van bloeddruk en extracellulair volume in de pathogenese en de behandeling

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 5, 2004, Pages 212-217

  Braam, B ^a,b   De Koning, E J ^a,c   Mees, E J Dorhout ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Afd Nierziekten en Hypertensie   (Netherlands)

^c Diab/Endocrin ^*

^d NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOREGULATION; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; EXTRACELLULAR SPACE; GLOMERULOPATHY; HUMAN; KIDNEY FAILURE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; PATHOGENESIS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; TREATMENT INDICATION;

EID: 0842307621     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989;4:859-63.
2. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes. A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
3. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346:1080-4.
4. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;11:309-17.
5. Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens 2001;23:45-55.
6. Weston PJ, James MA, Panerai RB, McNally PG, Potter JF, Thurston H. Evidence of defective cardiovascular regulation in insulin-dependent diabetic patients without clinical autonomic dysfunction. Diabetes Res Clin Pract 1998;42:141-8.
7. Ditzel J, Lervang HH, Brochner-Mortensen J. Renal sodium metabolism in relation to hypertension in diabetes. Diabetes Metab 1989;15(5 Pt 2):292-5.
8. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000;36:449-67.
9. Christensen PK, Hommel EE, Clausen P, Feldt-Rasmussen B, Parving HH. Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies. Kidney Int 1999;56:1517-23.
10. Hannedouche TP, Delgado AG, Gnionsahe DA, Boitard C, Lacour B, Grunfeld JP. Renal hemodynamics and segmental tubular reabsorption in early type I diabetes. Kidney Int 1990;37:1126-33.
11. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996;49:1774-7.
12. Strojek K, Grzeszczak W, Lacka B, Gorska J, Keller CK, Ritz E. Increased prevalence of salt sensitivity of blood pressure in IDDM with and without microalbuminuria. Diabetologia 1995;38:1443-8.
13. Miller JA. Renal responses to sodium restriction in patients with early diabetes mellitus. J Am Soc Nephrol 1997;8:749-55.
14. Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early [corrected] type I diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 2003;14:530-7.
15. Weidmann P, Ferrari P. Central role of sodium in hypertension in diabetic subjects. Diabetes Care 1991;14:220-32.
16. Molyneaux LM, Willey KA, Yue DK. Indapamide is as effective as captopril in the control of microalbuminuria in diabetes. J Cardiovasc Pharmacol 1996;27:424-7.
17. Viberti G, Mogensen C, Ritz E, Halimi S, Ruilope L, Jermendy G, et al. Treatment based on a very low dose combination of perindopril and indapamide reduces albuminuria more effectively than enalapril in hypertensive type 2 diabetic patients: the PREMIER study. Diabetologica 2002;45 Suppl 2:A65.
18. Tuomilehto J. Preventing cardiovascular disease in hypertensive patients with type 2 diabetes: is there a superior antihypertensive therapy? J Hypertens 2000;18:1553-6.
19. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-12.
20. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Circulation 2002;106:672-8.
21. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9.
22. Guidelines Committee. 2003 European Society of Hypertension -European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
23. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002;51:3274-82.
24. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
25. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998;21:104-10.
26. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type I diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 1999;34:809-17.
27. Lansang MC, Price DA, Laffel LMB, Osei SY, Fisher NDL, Erani D, et al. Renal vascular responses to captopril and to candesartan in patients with type i diabetes mellitus. Kidney Int 2001;59:1432-8.
28. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
29. Brenner BM, Cooper ME, Zeeuw D de, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
30. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. N Engl J Med 2001;345:870-8.
31. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910-2.
32. Kurtzman NA. Drug companies should not have the final say in the design of clinical trials. Am J Kidney Dis 2001;38:1113-4.
33. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.